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Background and aims: We assessed the possibility to rule out negative urine cultures by counting with UriSed 3 
PRO (77 Elektronika, Hungary) at Helsinki and Uusimaa Hospital District. 
Materials and methods: Bacteria counting of the UriSed 3 PRO automated microscope was verified with reference 
phase contrast microscopy against growth in culture. After acceptance into routine, results of bacteria and 
leukocyte counting from 56 426 specimens with eight UriSed 3 PRO instruments were compared against results 
from parallel samples cultured on chromogenic agar. Laboratory data including preanalytical details were 
accessed through the regional database of the Helsinki and Uusimaa Hospital District. 
Results: A combined sensitivity of 87–92% and a negative predictive value of 90–96% with a specificity of 
54–50% was reached, depending on criteria. Preanalytical data (incubation time in bladder) combined with the 
way of urine collection would improve these figures if reliable. 
Conclusions: Complex patient populations, regional logistics and data interfases, and economics related to 
increased costs of additional particle counts against costs of screening cultures of all samples, did not support 
adaptation of a screening process of urine cultures. This conclusion was made locally, and may not be valid 
elsewhere.   
1. Introduction 
Rapid screening of bacteriuria has interested both clinical units and 
laboratories, since urinary tract infections (UTI) are prevalent in emer-
gency patients, and laboratories are willingly improving their turn-
around times and efficiency by avoiding unnecessary cultures of 
negative samples [1]. Application of flow cytometry to rule out negative 
bacterial cultures has been developed during the last 20 years [2–9]. 
Sufficient sensitivity for such a use is also claimed for some automated 
image analysers, including previous models of UriSed/sediMAX analy-
sers [10–13]. Definition of a significant growth varies between 105–108 
CFB/L (colony-forming bacteria/liter, equivalent to 102–105 CFU/mL) 
in the criteria of the ECLM European urinalysis guidelines [14]. Also the 
American guideline for clinical trials on new anti-infective drugs for UTI 
recommends a combined approach in the interpretation of positive urine 
cultures from mid-stream samples, including clinical presentation 
(cystitis vs pyelonephritis), symptoms related to UTI such as dysuria, 
gender and age, as well as the types of isolated species or mixed growth 
[15]. Furthermore, economic factors of local health care system affect 
the outcome of any assessments of bacteriuria screening [16]. 
We verified the performance of a new model of UriSed automated 
microscope called UriSed 3 PRO (also sediMAX conTRUST PRO; 77 
Elektronika, Budapest, Hungary) with phase-contrast images on urine 
particles [17] for routine particle analysis in HUSLAB regional 
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laboratories. In addition to particle counting in laboratories of the 
Department of Clinical Chemistry, a total of eight UriSed 3 PRO in-
struments at Helsinki and Uusimaa regional laboratories were tested in 
their capability to rule out negative bacterial cultures at the Department 
of Clinical Microbiology of HUSLAB, Helsinki, for a possibility to 
screening about 310 000 urine cultures annually. 
2. Materials and methods 
2.1. Urine samples 
Parallel urine specimens, one for particle analysis and the other for 
bacterial culture, were collected into 10 ml boric acid, sodium formate 
and borate preservative tubes (C&S, BD Preanalytical Solutions, Eysins, 
Switzerland, cat no 364955), and transported regionally from patients’ 
homes, primary care sites, or regional hospital units to the nearest 
regional laboratory, or to the Meilahti central laboratory at room tem-
perature (with temperature loggers inside the boxes that were located 
within the warmed spaces of the vans). Particle analysis was carried out 
within 8 h from sample collection [18], and bacterial cultures were 
initiated within 24 h from collection. 
2.2. Automated microscopy with UriSed 3 PRO 
The automated UriSed 3 PRO has been previously described [17]. 
The model 3 PRO with improved phase contrast optics was first 
launched in April 2018, and HUSLAB received its instruments among the 
first customers (eight for Helsinki and Uusimaa Hospital District and two 
for Kymenlaakso Hospital District, not included in this study). Bacteria 
(BAC) are not counted individually by UriSed 3 PRO, but by software 
assessing details in the 15 grids of 960 × 1280 pixels. In that sense, BAC 
count is an arbitrary value related to concentration of bacteria-like 
particles. That is why we wanted to verify the performance of the first 
UriSed 3 PRO instrument (“Gold”) against growth in culture, and 
compare those figures to reference microscopy of limited number of 
urine samples against culture, before taking into routine use. 
After verification, local flagging limits (=autoverification rules) 
were adopted for routine particle counting to solve uncertainties or re-
view flags provided by the instrument in about 30% of HUSLAB routine 
samples (see Supplementary material A for detail of the HUSLAB flag-
ging limits). The eight UriSed 3 PRO were verified and taken into routine 
use with a software version 4.1.29 after modifications in data transfer. 
Results of region-wide samples of this study were taken from patient 
database, i.e., after reviews by human operators and releases to labo-
ratory information system in HUSLAB laboratories. In internal quality 
control, commercial control solutions (KOVA®Liqua-Trol™ with Mi-
croscopics; Kova International, Amsterdam, The Netherlands) were 
used. Day-to-day repeatability of RBC counts was 8.4% at 350 RBC ×
106/L and 15.7% at 55 RBC × 106/L using the control material. The 
corresponding figures for WBC counts were 8.4% at 211 × 106/L and 
15.2 at 48 WBC × 106/L. Imprecision targets included consideration of 
theoretical Poisson distributions of low counts. Linearity was verified for 
natural RBC up to 2000 × 106/L and for WBC up to 3600 × 106/L with 
R2 = 1.00. No carry-over was demonstrated to RBC, WBC or BAC counts. 
Laboratory report included white blood cells (WBC), red blood cells 
(RBC), bacteria (BAC), squamous epithelial cells (SEC), non-squamous 
epithelial cells (NEC), and casts (CAST, combining hyaline, HYA, and 
pathological, PAT casts), while other particle classes provided by the 
instrument were used for flagging limits only. Ordinal scale agreements 
with weighted kappa coefficients were the following: WBC 0.94, RBC 
0.89, SEC 0.88, CAST 0.59 and NEC 0.49. Agreement of BAC counts with 
reference procedures is reported in this paper. 
2.3. Visual microscopy 
In primary verification for laboratories in Helsinki and Uusimaa 
Hospital District, automated results of the first UriSed 3 PRO instrument 
(called “Gold”) were verified against visual microscopy. The other seven 
instruments (called “Silver” instruments) were verified sequentially 
against the first one using parallel samples. The reference microscopy 
with phase contrast optics was performed by four authors, each sample 
counted only once and by one author, but the interobserver variability of 
the experienced microscopists was controlled before the study, espe-
cially with regard to bacteria quantitation. We used a modified ISLH 
reference procedure with disposable 1 µL Bürker chambers (Cell Vision 
Technologies, SB Heerhugowaard, The Netherlands; product code CV- 
1000-B) and a modification from the ISLH reference procedure [19]: a 
maximum of 1 µL of uncentrifuged, unstained urine sample was counted 
after resuspension, independently of particle counts. As a novelty, 
quantitative estimates on bacteria counts were obtained by using either 
B or D squares of the Bürker chamber with 1/160 µL or 1/4000 µL 
volume, respectively (see Supplementary material B for detail). Two 
bacteria in B square corresponded to 320 bacteria/µL (limit of a “posi-
tive” result), and two bacteria in D square corresponded to 8000 bac-
teria/µL (limit of an “abundant” result). 
2.4. Urine bacterial cultures 
Parallel specimens were available for bacterial culture at the 
Department of Clinical Microbiology. The urine samples were cultured 
by using automated inoculation with 1 µL loop (WASP® automated 
microbiology instrument, COPAN Wasp, Brescia, Italy) on chromogenic 
agar plates (CHROMagar™ Orientation medium, RT413-25, CHROMa-
gar, Paris, France), following incubation at 35 ◦C for 18 h. Limit of 
significant growth was defined as (1) generally at 107 CFB/L (SI unit, 
corresponding to 104 CFU/mL) or more, and 1–2 identified species of 
common urinary pathogens or mixed growth, independently of type of 
collection, based on the current practice, or (2) experimentally, using 
other definitions of significant growth, and provisionally a short incu-
bation time (less than 4 hours) in bladder as a sign of dysuria for 
midstream urine (MSU) specimens, as provided by the electronic re-
quests. In those MSU specimens, a significant growth was additionally 
defined as 106 CFB/L (SI unit, corresponding to 103 CFU/mL) or more 
with 1–2 identified species reflecting the ECLM European urinalysis 
guidelines [14]. Mixed growth was treated either as negative or positive 
result as indicated in the text or tables. 
After the primary verification of bacteria counting of the Gold in-
strument with 396 of samples (see Supplementary material B) in 
September and October 2018, the other seven “Silver” instruments were 
verified against it with parallel samples before clinical use by March 
2019. The district-wide evaluation of performance of bacteria screening 
was carried out within the Helsinki and Uusimaa Hospital District by 
comparing 56 426 reported routine results (after reviews of the opera-
tors based on created flagging limits) from eight UriSed 3 PRO in-
struments with parallel bacterial culture results from April to September 
2019. Samples with no parallel results or no quantitative counts (e.g., 
crowded sample, or too much amorphous precipitate) from either pro-
cedure were excluded. 
2.5. Data analysis 
Data were collected from different analyzers and combined on 
Microsoft Excel spreadsheets. Sample IDs were used to combine the 
results from parallel samples and the preanalytical data of the encrypted 
patients at the IT department of the Helsinki and Uusimaa Hospital 
District. Statistics from Analyze-It® software (Analyse-it Software Ltd., 
England) was used as a module of Microsoft Excel spreadsheets as 
needed. 
Non-parametric Spearman’s correlation coefficients were calculated 
for quantitative counts (WBC and RBC). Ordinal scale agreement was 
assessed by weighted Cohen’s kappa coefficients from cross-tabulated 
classified data. 
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The large regional database with encrypted personal IDs was 
requested and constructed by utilizing the comprehensive database of 
the Helsinki and Uusimaa Hospital district (including laboratory data), 
out of approximately 310 000 annually cultured samples. This allowed 
comparisons of patients’ demographic data, ways of sample collection, 
bladder incubation times, and particle counting results with those from 
screening cultures and identified microbial species. Automated formulas 
on Excel spreadsheets were created to calculate sensitivities and speci-
ficities against culture growth, with different thresholds of UriSed 3 PRO 
counts for WBC and bacteria. 
Results were received from 4935 children (less than 15 years of age, 
61.4% girls) and 51 591 adults (15–100 years of age, 51.7% women). 
The specimens were sent from hospital emergency rooms in 30%, hos-
pital departments in 45%, and from various primary care sites in 25% of 
cases. The way of collection was explicitly reported in the database for 
13 630 samples (24.2% of all cases). Of those samples, midstream urine 
(MSU) collection constituted 76.5%, single catheterization 10.7% and 
indwelling catheter 8.8% of cases. From the reported 1007 pediatric 
samples, 80.3% were MSU collections, 9.6% bag urine and 5.8% spon-
taneously voided infant specimens. Bladder puncture specimens were 
excluded from the study. 
3. Results 
3.1. Verification of UriSed 3 PRO bacteria counting 
Detailed performance of UriSed 3 PRO bacteria counting was not 
extensively studied when we received that instrument model in 2018. As 
a necessary step before clinical use, the performance of the first UriSed 3 
PRO instrument (“Gold”) bacteria counting was assessed against urine 
bacterial cultures. In addition, a parallel study was performed with a 
developed reference visual microscopy in a Bürker chamber with 
different patient samples (see Supplementary material B). At a ruling- 
out limit of 80 × 106/L of BAC counts, UriSed 3 PRO reached a sensi-
tivity of 90% with a specificity of 39% against culture, and at a ruling-in 
limit of 800 × 106/L, a specificity of 96% with a sensitivity of 24% 
against culture. The performance shown by a receiver-operating char-
acteristic (ROC) curve was remarkably similar to that obtained by visual 
reference microscopy with phase contrast optics (see the Supplementary 
material B). The other seven UriSed 3 PRO instruments (“Silver” in-
struments) in HUSLAB laboratories of Helsinki and Uusimaa Hospital 
District were assessed then against the primary instrument (Gold) before 
clinical use. 
3.2. Comparison of multiple UriSed 3 PRO instruments against bacterial 
culture 
The capability of UriSed 3 PRO to screen bacteriuria from clinically 
reported samples was assessed using 56 426 specimens with parallel 
requests and tubes for urine particle analysis and bacterial culture, and 
quantitative results from both assays. Urine cultures resulted in 29 279 
(51.9%) samples with no growth, 16 055 (28.5%) samples with mixed 
growth, and 11 092 (19.7%) samples with identified species (Table 1) 
and antimicrobial susceptibility testing. The patient populations from 
emergency rooms, specialized and primary health care had a 55% 
occurrence of E. coli isolates. 
True positive (TP) or false positive (FP) fractions against bacterial 
culture were calculated separately for each category of culture growth at 
each limiting BAC count of UriSed 3 PRO (Fig. 1). In this way, it was 
possible to see the impact of increasing colony counts 106 – 108 CFB/L 
(or 103 – 105 CFU/mL) and types of growth (1–2 identified species, or 
mixed growth) on detection of bacteria. When counting unselectively 
bacteria-like particles, the specificity (rate of FP cases) against selective 
urine cultures becomes important. The shaded zone of 60–80 BAC ×
106/L delineated the range where FP rate from negative cultures 
reached the limit of a useful test of about 50% (FP rate increased from 
Table 1 
Identified species from urine cultures. In cases with two identified species, the 
more important uropathogen was taken into the list.   
N % 
Escherichia coli 6092 54.9% 
Enterococcus faecalis 815 7.3% 
Klebsiella pneumoniae 743 6.7% 
Staphylococcus. not sapr. not aureus 523 4.7% 
Pseudomonas aeruginosa 310 2.8% 
Gram positive cocci. not specified 269 2.4% 
Streptococcus agalactiae 240 2.2% 
Klebsiella oxytoca 199 1.8% 
Proteus mirabilis 192 1.7% 
Lactobacillus spp. 180 1.6% 
Citrobacter spp. 164 1.5% 
Enterobacter cloacae 138 1.2% 
Staphylococcus aureus 122 1.1% 
Staphylococcus saprophyticus 112 1.0% 
Enterococcus faecium 107 1.0% 
Streptococcus viridans spp. 96 0.9% 
Citrobacter freundii 95 0.9% 
Aerococcus urinae 86 0.8% 
Enterobacter aerogenes 66 0.6% 
Morganella morganii 55 0.5% 
Candida albicans 51 0.5% 
Gram negative coliform rods 35 0.3% 
Serratia marcescens 34 0.3% 
Enterobacter spp. 30 0.3% 
Proteus vulgaris 29 0.3% 
Staphylococcus lugdunensis 28 0.3% 
Raoultella ornithinolytica 25 0.2% 
Gram negative rods. not specified 22 0.2% 
Klebsiella spp. 19 0.2% 
Acinetobacter spp. 18 0.2% 
Aerococcus sanguinicola 17 0.2% 
Others 180 1.6%  
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Fig. 1. Diagnostic performance of UriSed 3 PRO Bacteria (BAC) counting 
against urine bacterial culture (n = 56 426 specimens). Cumulative percentage 
of true positives (sensitivity) at each limiting BAC count against culture is 
shown for each category of positive growth, and that of false positives (1- 
specificity) against negative culture. Culture results were converted to a SI unit 
colony-forming bacteria/liter (CFB/L) by adding three exponentials, e.g., 107 
CFB/L = 104 CFU/mL. Labels (and the corresponding numbers of specimens) of 
each category of growth were as follows: Negative culture, Negat (29 279 
specimens), M6 = 106 CFB/L Mixed growth (9 139), S6 = 106 CFB/L with 1–2 
Species identified (622), M7 = 107 CFB/L Mixed growth (5 701), S7 = 107 
CFB/L with Species identified (2 202), M8 = 108 CFB/L Mixed growth (1 215), 
and S8 = 108 CFB/L with Species identified (8 268 specimens). The limiting 
zone for specificity ≥50% with UriSed 3 PRO BAC at 60–80 × 106/L is marked 
with a grey shading. 
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42% to 52%) (Fig. 1). The colony count used to define a positive result in 
culture had a major role in defining the sensitivity (TP fraction) by 
UriSed 3 PRO, while almost no difference was observed in sensitivities 
between cultures with identified species and those with mixed growth 
(Fig. 1). With bacterial growth at 108 CFB/L (both identified species and 
mixed growth), a combined sensitivity of 93–97% was reached by using 
a BAC cut-off of 70–80 × 106/L. A stepwise reduction of sensitivity was 
seen down to 69–75% at 107 CFB/L, and to 50–56% at 106 CFB/L with a 
similar specificity when each category of growth was assessed separately 
(Fig. 1). 
Detection of bacteriuria might be improved by using both WBC and 
BAC counts in screening. Detection of bacterial growth at 107 CFB/L 
(104 CFU/mL) or more, including mixed growth, succeeded with UriSed 
3 PRO with a sensitivity of 64% and specificity of 85% at a cut-off of 30 
WBC × 106/L alone, by UriSed 3 PRO. A WBC count of 15 × 106/L was 
the limit of quantitation of patient samples with UriSed 3 PRO (un-
published results). At the highest cut-off of 108 CFB/L (105 CFU/mL) in 
culture, a sensitivity of 82% with a specificity of 80% was obtained at 30 
WBC × 106/L by UriSed 3 PRO. The sensitivity of WBC to detect 
bacteriuria at 106 CFB/L (103 CFU/ml) was 75%, i.e., better than that at 
107 CFB/L, when cultures with mixed growth were ignored. The detail at 
different cut-offs of WBC counts at 20–50 × 106/L alone, and definitions 
of positive growth is shown in the Supplementary material C. 
3.3. Screening of bacteriuria with combined UriSed 3 PRO results 
An optimum combination to rule out negative bacterial cultures was 
sought by repeated calculations with automated Excel formulas at var-
iable cut-off limits of BAC and WBC counts, using results from 56 426 
regional samples. The performance of UriSed 3 PRO against all growth at 
107 CFB/L (the current practice) or more is shown in a set ROC curves, 
modified by WBC counts (Fig. 2). It is seen that WBC counts had almost 
no impact in the outcome of performance. To guarantee a specificity 
>50%, the following UriSed 3 PRO limits were selected for performance 
assessment for regional practice: WBC 50 × 106/L and BAC 80 × 106/L. 
The definition of significant bacteriuria was varied from the current 
local practice, yielding into different sensitivities (Table 2). By using the 
chosen UriSed 3 PRO limits, an estimate of 41% of routine samples (23 
087/ 56 426) could be ruled out from urine cultures, and 59% would be 
cultured after counting. At HUSLAB, this would mean 127 000 samples 
sorted out of 310 000 annual routine cultures, leaving 183 000 samples 
for culture. A sensitivity of 87% with the Panel A (defining all growth 
significant at 107 CFB/L or more) could be increased to 92% by using the 
Panel B (all growth at 108 CFB/L significant, but samples with lower CFB 
at 106/L or 107/L defined significant if specific species were identified 
only). This would reduce the number of false negative (FN) samples from 
2214 to 980 cases and lead into a NPV of 96%. Further improvement of 
sensitivity of bacteriuria screening up to 98%, and NPV up to 99% would 
be seen by classifying only the cultures at 108 CFB/L as significant 
(Panels C-D), with no major difference in classification of samples with 
mixed growth (Table 2). Thus, the sensitivity increased from 87% to 
98%, while the specificity fell from 54% to 48% with different criteria. 
Negative predictive value (NPV) increased concomitantly from 90% to 




















Fig. 2. Performance of UriSed 3 PRO combined BAC and WBC counts to detect 
significant growth in culture, defined as 107 CFB/L or more colonies of iden-
tified species or mixed growth, according to the local practice. Out of the 
56 426 urine samples, 16.8 % grew at 108 CFB/L and 14.0% at 107 CFB/L or 
more in culture, as combined from the caption of Fig. 1. The receiver-operating 
characteristic (ROC) curves were focused around the sensitivity of 90%. The 
ROC curves show diagnostic performance of various BAC counts at the limiting 
WBC concentrations of 10, 20 or 50 × 106/L. The cut-off point with a specificity 
of 50% at BAC 80 × 106/L is shown. 
Table 2 
Diagnostic performance of UriSed 3 PRO combined BAC and WBC counts in detecting bacteriuria by using different definitions of significant growth (A-D). Cut-off 
limits of positive UriSed 3 PRO counts were BAC 80 × 106/L and WBC 50 × 106/L. NPV and PPV = negative and positive predictive values.  
A. Significant growth 107 CFB/L or more, B. Significant growth 106 CFB/L or more 
including mixed growth with identified species plus mixed growth at 108 CFB/L   
Culture   Culture  
UriSed3PRO POSIT NEGAT Total POSIT NEGAT Total 
Posit 15,172 18,167 33,339 11,327 22,012 33,339 
Negat 2214 20,873 23,087 980 22,107 23,087 
Grand Total 17,386 39,040 56,426 12,307 44,119 56,426 
Prevalence 30.8%   21.8%   
Sensitivity 87.3% NPV 90.4% 92.0% NPV 95.8% 
Specificity 53.5% PPV 45.5% 50.1% PPV 34.0%  
C. Significant growth 108 CFB/L or more, D. Significant growth 108 CFB/L or more 
including mixed growth with identified species only   
Culture   Culture  
UriSed3PRO POSIT NEGAT Total POSIT NEGAT Total 
Posit 9248 24,091 33,339 8102 25,237 33,339 
Negat 235 22,852 23,087 166 22,921 23,087 
Grand Total 9483 46,943 56,426 8268 48,158 56,426 
Prevalence 16.8%   14.7%   
Sensitivity 97.5% NPV 99.0% 98.0% NPV 99.3% 
Specificity 48.7% PPV 27.7% 47.6% PPV 24.3%  
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only as they do not comply with the European and American guidelines 
for significant growth. 
Additionally, several guidelines point out the importance of clinical 
symptoms of UTI and preclinical detail of urine specimens in assessing 
significance of bacteriuria. We modelled symptoms of patients by using 
the available bladder incubation times in electronic laboratory requests 
to classify urgency. For MSU samples, a lower level at 106 CFB/L should 
be considered significant growth if patients suffered from dysuria (short 
incubation time in bladder), while a higher level of 108 CFB/L is 
applicable for patients with no urgency symptoms (reflected by an in-
cubation time at least for 4 h) [14]. From the 980 FN cases (Panel B in 
Table 2), all MSU specimens with information on a bladder incubation 
time for 4 h or more (absence of urgency) were reclassified as true 
negatives if the growth in culture was less than 108 CFB/L. By this cri-
terion, the amount of FN cases was reduced to 532 patients, and NPV 
was increased from 96% to 98%. 
3.4. Prediction of mixed growth by squamous epithelial cell (SEC) counts 
High concentrations of SEC in urine have been suggested to predict 
non-significant result in culture. Distributions of SEC counts in the 
available 39 035 MSU specimens (when no coded information was 
assumed to represent a MSU collection) with different categories of 
growth is shown in Fig. 3. Among MSU samples with negative culture 
result, the 95% upper reference limit was 9 SEC × 106/L. With 
increasing CFB/L in culture, the 95th percentile of SEC counts increased 
up to 55 SEC × 106/L in samples with mixed growth at 108 CFB/L. The 
90th percentile in the last group was 40 SEC × 106/L (marked in Fig. 3). 
SEC at 40 SEC × 106/L or more were seen in 1.2% of the MSU samples. 
These were divided as follows: 160 in 2531 specimens with mixed 
growth (6.3% sensitivity to predict mixed growth), 279 /7619 (3.7%) in 
specimens with identified species, and 208/28,885 (0.7%) in samples 
that remained negative in culture. The positive predictive value (PPV) of 
the SEC cut-off at 40 × 106/L in indicating mixed growth was only 
24.7%. Using a cut-off of 60 SEC × 106/L, a sensitivity of 2.7% to detect 
mixed cultures was obtained, with a PPV still at 25.5% only (detail not 
shown). 
4. Discussion 
4.1. Analytical assessment 
In the verification, the installed UriSed 3 PRO instruments fulfilled 
the quality specifications of trueness and precision for counting of urine 
RBC, WBC, and SEC [27]. Improved detection of bacteria was developed 
in visual microscopy, by using the D squares in Bürker chambers 
(1/4000 µL), and peer practicing to reach reproducible counts among 
observers (Supplementary material B). A sensitivity of 89% as compared 
to 107 CFB/L in culture exceeds microscopy in most routine laboratories. 
A similar sensitivity and specificity against urine cultures was reached 
with phase contrast optics of UriSed 3 PRO, which was important in 
confirming the accuracy of pixel-based BAC counts of the instrument. 
The flagging limits (Supplementary material A) adapted for routine 
counting with UriSed 3 PRO included visual confirmation of all abun-
dant BAC counts (800 or more × 106/L), and improved bacteria 
counting of samples with amorphous precipitates by dilution of speci-
mens, by using on-screen reviews of automated images, and occasional 
visual microscopy as needed. 
The performance of BAC parameter of the eight UriSed 3 PRO in-
struments in screening for bacteriuria was tested with laboratory data of 
56 426 samples from the region-wide patient database of Helsinki and 
Uusimaa Hospital District. The identified bacterial species was E. coli in 
55% of 11,092 samples (Table 1). In combined definitions of significant 
growth, the fraction of samples with low colony counts, and classifica-
tion of mixed growth into significant or non-significant have a major 
impact in the observed sensitivity of screening against urine culture. 
When testing the growth categories separately, we reached a sensitivity 
of 93–97% at 108 CFB/L, a sensitivity of 69–75% at 107 CFB/L, or a 
sensitivity of 50–56% at 106 CFB/L with a similar specificity of about 
50–55% by UriSed 3 PRO BAC counts (Fig. 1). In addition to sensitivity, 
details of the measurement principle in a particle analyzer set the frame 
for specificity of bacteria detection achieved against cultures that are 
carried out on selective media. 
Antimicrobial treatment might have affected specificity of BAC 
counting, but we were not able to evaluate the magnitude of that effect. 
In Finland, there is a general guidance to obtain a sample for urine 
culture before an empiric treatment, but information on current anti-
microbial treatment is rarely recorded in the electronic requests. That is 
why samples with antimicrobial treatment could not be studied sepa-
rately, to see the role of dead bacteria on the performance. 
At the highest threshold of significant growth at 108 CFB/L (both 
identified species and mixed growth from Fig. 1), a sensitivity of 96% 
with a specificity of 52% was reached with UriSed 3 PRO by using the 
BAC channel alone. As a comparison, the latest flow cytometer tech-
nology of Sysmex UF-5000 has provided a sensitivity of 99% with a 
specificity of 80% at the same cut-off limit of growth, using samples 
from hospital patients [8]. A stepwise reduction of sensitivity was seen 
with lower CFB/L limits, as shown also for UF-5000 [20]. Our primary 
definition for a significant bacteriuria was the current practice with 
routine screening of all growth at 107 CFB/L or more. By the BAC 
channel alone, bacteriuria at that limit was shown with a sensitivity of 
87% and a specificity of 51%. 
Leukocyte detection has traditionally been used to screen for 
bacteriuria with test strips or microscopy. A sensitivity of 58–69% with a 
specificity of 89–81% was seen by using WBC counts at a range of 
20–50 × 106/L against any growth at 107 CFB/L or more in culture 
(Supplementary material C). UriSed BAC counts have been shown to be 
more sensitive than WBC counts in detecting bacteriuria also in another 
study of patients at a university hospital [12]. BAC and WBC counts 
analyzed with the Sysmex UF-500i flow cytometer at a general hospital 
have shown similar results [21]. Large centralized laboratories seem to 
receive specimens from a wide range of clinical situations, including 
differential diagnostics of various symptoms. The insensitivity of WBC 







Negat S6 M6 S7 M7 S8 M8
Urine SEC x106/L
Growth in culture, 10X CFB/L
SEC 40 x106/L
Fig. 3. Value of squamous epithelial cells (SEC) in predicting mixed growth in 
culture assessed from available mid-stream urine (MSU) specimens (n = 39 
035). The bars show 95th percentiles and the whiskers 99th percentiles of urine 
SEC counts in each category of growth. The number of MSU specimens in each 
group was as follows (given in brackets): Negat = Negative culture (28 885), S6 
= 106 CFB/L with Species identified (504), M6 = 106 CFB/L Mixed growth 
(465), S7 = 107 CFB/L with Species identified (1 635), M7 = 107 CFB/L Mixed 
growth (1 367), S8 = 108 CFB/L with Species identified (5480), and M8 = 108 
CFB/L Mixed growth (699 specimens). 
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WBC that are most easily counted by all particle analyzers. Also UriSed 3 
PRO reached a sensitivity of 95% with a specificity of 90% at 30 WBC ×
106/L, or a sensitivity of 92% with a specificity of 77% at 10 WBC × 106/ 
L against our reference microscopy [27]. The apparent insensitivity of 
WBC is associated with lack of pyuria among samples sent to urine 
bacterial culture. Foudraine et al. have shown that in an academic center 
almost half of the samples may be requested from patients not suspected 
for UTI [22]. 
A combined performance of BAC and WBC counts is usually of value 
when maximizing the sensitivity of automated particle counting in 
bacteriuria screening. In our collection of regional results, the ROC 
curves with various WBC concentrations did not, however, show any 
clear difference in the sensitivity or specificity of bacteriuria detection 
with our definition of significant growth (Fig. 2). The ROC curves also 
showed how the achieved sensitivity is obtained with loss of specificity 
against culture. With the ROC curve, we could compare performance of 
UriSed 3 PRO with that of an older version of the UriSed instrument: The 
current version provided a sensitivity of about 72% with a specificity of 
80%, as compared with a sensitivity of 56% and a specificity of 81% in 
2013, although those authors do not reveal the size of the fraction of 
low-colony counts included in their study [23]. Optimized screening 
with BAC counts at 80 × 106/L and WBC counts at 50 × 106/L by UriSed 
3 PRO would result in a sensitivity of 87% and NPV 90% (Panel A in 
Table 2) that is similar to the values without WBC counts. A sensitivity of 
92% and NPV of 96% at a prevalence of 22% of positive cases was 
reached at 106 CFB/L or more by including samples with identified 
species only, and also mixed growth at the highest level of 108 CFB/L 
(Panel B of Table 2). Compared to the current practice (Panel A), the 
verified sensitivity was considered insufficient, because more than 10% 
of cultures with significant growth remained negative. Additionally, 
about 50% of isolates at the lowest 106 CFB/L category (including 622 
samples with identified species) would have remained undetected if 
screened with the UriSed 3 PRO (Fig. 1), creating a need of special 
requisition and laboratory processes for clinically important suspicions 
of low-colony count bacteriuria if applied. The highest cut-off of 108 
CFB/L with a sensitivity of 98% and NPV of 99% (Panels C and D in 
Table 2) were calculated for technical comparisons against other in-
struments. Mixed growth in culture is suggested to represent borderline 
significance for high-risk patients who may not be able to provide non- 
contaminated samples in all clinical situations, despite being considered 
non-significant in the assessment of new drugs for UTI [15]. 
Elimination of samples with high SEC counts from the assessment of 
bacteriuria has been suggested to improve the diagnostic performance of 
automated counting [24], since those samples are considered to repre-
sent urine from external genitalia rather than MSU, and to associate with 
mixed growth. Among the 39 035 MSU samples of this study, the SEC 
counts of different categories of growth were highly overlapping, 
resulting in a PPV of only 25% for SEC at 40 × 106/L or higher in pre-
dicting mixed growth, with a sensitivity of 6% (Fig. 3). The PPV did not 
improve at SEC 60 × 106/L. Thus, high SEC counts did not predict mixed 
culture results. A similar result has been obtained also in another study 
with retrospective data on 19 300 samples [25]. Samples with high SEC 
counts may still indicate that the observed growth is not representing 
bladder urine independently of the outcome. 
Preanalytical information should be utilized to reduce the number of 
irrelevant clinical interpretations, despite challenges of high-quality 
evidence [26]. When the way of collection (MSU) and time of urine in 
bladder (with a cut-off of 4 h for absence of urgency) were reliably 
included in the classification of significant growth, the false negative 
rate at low CFB/L samples could be reduced. Consequently, the NPV at 
106 CFB/L (without mixed cultures) improved from 96% to 98%, with 
the specificity remaining still at around 50% (Table 2, panel B). Iñigo 
et al. [12] demonstrated a sensitivity of 96% and NPV 98% with a 
specificity of 63% for SediMAX (UriSed) against growth of identified 
species at a cut-off of 105 CFB/L (102 CFU/mL) in their population of 
hospital patients, by using additional clinical data suggestive of UTI. As 
a comparison, a sensitivity of 98% with a specificity of 52% was ob-
tained with Sysmex UF-1000i flow cytometer, optimizing criteria for 
significant growth based on the European guidelines in a Swedish 
tertiary-level regional laboratory service in Umeå [7]. Age and sex- 
specific cut-off limits of counts have resulted in a sensitivity up to 
97% with a specificity of 78% with a Sysmex 500i analyzer, using 
tailored definitions of positive culture in a second-level regional Finnish 
setting in Lahti [6]. The obtained specificity is highly dependent on the 
health care environment and is affected by patients and types of samples 
used in the assessments. Consequently, the Finnish criteria from Lahti 
provided a specificity of 78% in Lahti, but a specificity of 41% only, 
when applied in the Umeå laboratory [7]. 
4.2. Economical assessment 
In process planning, a new screening step should be sensitive enough 
to be applicable for most samples, sufficiently specific to result in 
exclusion of most true negative cases, and cheap enough to justify 
additional costs associated with a new step. Furthermore, costs of the 
changes including those of computer interfaces and resources needed for 
customer training must be considered. 
In urine cultures, samples from specific patient groups or those from 
specific ways of collection should be excluded from the screening pro-
cess. After that, most clinicians probably accept a general sensitivity or 
NPV of 95% or higher for screening of urine samples from non- 
immunocompromised individuals. We reached this level of NPV with 
UriSed 3 PRO by ignoring samples with mixed growth at 107 CFB/L 
(Table 2, Panel B), but not against the current definition of significant 
growth (Table 2, Panel A). The following detail on economical outcomes 
remained then provisional, e.g., for other laboratories considering 
economy in their environments. 
Specificity of screening offers savings that must be calculated against 
costs of a new screening step. If the screening test is already used for 
other purposes, the transitional costs for combining the screening test to 
urine cultures must be calculated. A diagnostic sensitivity of 90–95% 
with a specificity of 50–60% may work as a theoretical starting point for 
calculations. 
With a specificity of about 50%, we estimated to save about 40% of 
samples from culture work (Table 2). If half of samples was saved from 
the culture, the limiting cost of rational screening is 50% of the cost of 
main test, to remain equal to the situation without a screening step, 
because the screening is applied to all samples. The cost of bacteriuria 
screening (either by particle counting or test strip measurement) should 
be less than 50% of the cost of the culture because of various added costs 
into the process, to be economically viable. The ratio becomes more 
favorable if a test for bacteriuria screening is already done for other 
purposes. At HUSLAB service, the 310 000 annual urine cultures are 
currently being requested directly, independently of the 150 000 parti-
cle counts, and about 300 000 urine test strip measurements requested 
from the laboratories. In our case, a systematic bacteriuria screening by 
particle counting with the provided specificity was deemed to create 
extra costs both because of the current test requisition practice and 
because screening cultures from urine are not twice as costly to us as a 
new particle counting step. This differs from the situation in Sweden, 
where the relative cost of culture was estimated to be 5 times higher 
than that of flow cytometric screening, thus supporting the adaptation of 
the screening process in the laboratory [7]. Similarly, a Turkish com-
parison estimated 3 times higher unit costs in culture than in flow 
cytometry [16]. 
5. Conclusions 
Application of the eight UriSed 3 PRO particle analyzers provided a 
combined sensitivity of 87% and NPV of 90% only, with a specificity of 
53% against the current definition of significant growth at 107 CFB/L, 
including mixed growth. The performance could be theoretically 
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improved to NPV of 96–98% with a specificity of about 50% by ignoring 
mixed growth at low colony counts, and some midstream samples based 
on provisional preanalytical information. Despite successful adaptation 
of UriSed 3 PRO in large-scale particle counting at HUSLAB laboratories, 
the bacteriuria screening was not deemed economically satisfactory 
because of direct costs of the tests in question and indirect costs related 
to the complex healthcare environment and specific logistical needs. 
Instead, saving in patient care remained to be anticipated from clinical 
advice to order urine cultures and other urine tests with proper clinical 
presentation only, because of the high prevalence of bacteriuria with 
mixed growth. High-quality particle counting with UriSed 3 PRO was 
installed and is already available for clinicians needing rapid diagnostics 
in emergency cases. Our conclusion on bacteria screening with UriSed 3 
PRO is not applicable to other laboratories with less complex laboratory 
and health care environments, lower sample loads, different patient 
populations, or with different unit costs in their urine tests. 
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